Pneumococcal conjugate second or third-dose vaccines (PCVc) in Canada
Canada: Pneumococcal conjugate second or third-dose vaccines (PCVc) was 85.0% in 2025. ▲ Rising
Pneumococcal conjugate second or third-dose vaccines (PCVc) in Canada, 2008–2025
Source: World Health Organization, Global Health Observatory.
Analysis
The most recent figure for pneumococcal conjugate second or third-dose vaccines (pcvc) in Canada is 85.0%, measured in 2025. That is the highest value across all 18 years on record.
That represents a change of up 6.2% over ten years.
Over the whole period, pneumococcal conjugate second or third-dose vaccines (pcvc) in Canada peaked at 85.0% in 2022 and was at its lowest, 42.0%, in 2008.
That places Canada 96th out of 194 countries with data for 2025, putting it in the middle of the range.
The long-run direction has been consistently rising across the 18 years of available data.
Pneumococcal conjugate second or third-dose vaccines (PCVc) in Canada, year by year
| Year | Value | Change |
|---|---|---|
| 2008 | 42.0% | — |
| 2009 | 50.0% | +19.0% |
| 2010 | 58.0% | +16.0% |
| 2011 | 66.0% | +13.8% |
| 2012 | 73.0% | +10.6% |
| 2013 | 79.0% | +8.2% |
| 2014 | 79.0% | +0.0% |
| 2015 | 80.0% | +1.3% |
| 2016 | 80.0% | +0.0% |
| 2017 | 81.0% | +1.2% |
| 2018 | 81.0% | +0.0% |
| 2019 | 84.0% | +3.7% |
| 2020 | 84.0% | +0.0% |
| 2021 | 84.0% | +0.0% |
| 2022 | 85.0% | +1.2% |
| 2023 | 85.0% | +0.0% |
| 2024 | 85.0% | +0.0% |
| 2025 | 85.0% | +0.0% |
Canada compared with similar countries
- Canada's 85.0% is below the median for high income countries, which is 91.0%, 93% of the median. (63 countries reporting)
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 46.0% | 42.0% | 50.0% | 2 |
| 2010s | 76.1% | 58.0% | 84.0% | 10 |
| 2020s | 84.7% | 84.0% | 85.0% | 6 |
Countries ranked near Canada
More health data for Canada
- Un projection of annual infant deaths, annual growth rate -1.79 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate -0.3588 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 1,083 deaths per 1,000 people (2090)
- Number of infants who die before age 1 385 deaths (2100)
- Neonatal tetanus - number of reported cases, gaps filled 0 (2025)
- Population ages 00-04, female, annual growth rate 0.5214 % change on previous year (2025)
- Population ages 00-04, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 00-04, female, per capita 0.023 units per person (2025)
- Population ages 00-04, male, annual growth rate 0.5024 % change on previous year (2025)
- Population ages 00-04, male, per unit of GDP 0 units per US$ of GDP (2025)
Frequently asked questions
- What is pneumococcal conjugate second or third-dose vaccines (pcvc) in Canada?
- Pneumococcal conjugate second or third-dose vaccines (pcvc) in Canada was 85.0% in 2025, according to World Health Organization, Global Health Observatory.
- What is the highest pneumococcal conjugate second or third-dose vaccines (pcvc) recorded in Canada?
- The highest recorded value was 85.0% in 2022.
- What is the lowest pneumococcal conjugate second or third-dose vaccines (pcvc) recorded in Canada?
- The lowest recorded value was 42.0% in 2008.
- How does Canada rank for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Canada ranks 96th out of 194 countries with data for 2025.
- Is pneumococcal conjugate second or third-dose vaccines (pcvc) rising or falling in Canada?
- Over the last ten years it is up 6.2%. The long-run trend across the full record is rising.
- Where does this Canada data come from?
- The figures come from World Health Organization, Global Health Observatory, published as part of Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 18 observations, free to reuse under CC BY-NC-SA 3.0 IGO (WHO).